Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced ...

Globus Medical, Inc. (NYSE:GMED – Free Report) – Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and ...

Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. However, the challenging macroeconomic scenario continues to plague Globus Medical.

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced Modulus ...

Joseph Mossel is the CEO of Ibex Medical Analytics. His career in the tech industry spans more than 20 years, starting off in ...